Since PI3K/Akt/mTOR signaling is hyperactivated in renal cell carcinoma (RCC), inhibition of PI3K/Akt/mTOR pathway is one of target for cancer treatment [19]–[21]. This evidence concerns the gene MTOR and hereditary clear cell renal cell carcinoma.